HYMPAVZI Patient Counseling Information
(marstacimab-hncq)
17 PATIENT COUNSELING INFORMATION
- •
- Advise the patient and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
- •
- Ensure that patients and caregivers who will administer HYMPAVZI receive appropriate training and instruction on the proper storage, use and handling of HYMPAVZI from a healthcare professional.
Thromboembolic Events
Inform patients and/or caregivers that HYMPAVZI increases coagulation potential. Discuss the appropriate dosing of concomitant agents such as FVIII or FIX with the patient prior to starting on HYMPAVZI prophylaxis [see Warnings and Precautions (5.1)]. Advise the patient to seek immediate medical attention if any signs or symptoms of thromboembolism occur.
Hypersensitivity
Inform patients and/or caregivers that hypersensitivity reactions such as rash and pruritus are possible. Advise patients to discontinue HYMPAVZI and seek immediate emergency treatment if a severe hypersensitivity reaction occurs [see Warnings and Precautions (5.2)].
Pregnancy
Advise female patients of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose. Advise patients to report known pregnancies [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)].
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
For medical information about HYMPAVZI, please visit www.pfizermedinfo.com or call 1-800-438-1985.
US License No. 2001
Distributed by
Pfizer Labs
Division of Pfizer Inc.
New York, NY 10001
LAB-1556-1.0
Find HYMPAVZI medical information:
Find HYMPAVZI medical information:
HYMPAVZI Quick Finder
Health Professional Information
Patient Counseling Information
17 PATIENT COUNSELING INFORMATION
- •
- Advise the patient and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
- •
- Ensure that patients and caregivers who will administer HYMPAVZI receive appropriate training and instruction on the proper storage, use and handling of HYMPAVZI from a healthcare professional.
Thromboembolic Events
Inform patients and/or caregivers that HYMPAVZI increases coagulation potential. Discuss the appropriate dosing of concomitant agents such as FVIII or FIX with the patient prior to starting on HYMPAVZI prophylaxis [see Warnings and Precautions (5.1)]. Advise the patient to seek immediate medical attention if any signs or symptoms of thromboembolism occur.
Hypersensitivity
Inform patients and/or caregivers that hypersensitivity reactions such as rash and pruritus are possible. Advise patients to discontinue HYMPAVZI and seek immediate emergency treatment if a severe hypersensitivity reaction occurs [see Warnings and Precautions (5.2)].
Pregnancy
Advise female patients of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose. Advise patients to report known pregnancies [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)].
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
For medical information about HYMPAVZI, please visit www.pfizermedinfo.com or call 1-800-438-1985.
US License No. 2001
Distributed by
Pfizer Labs
Division of Pfizer Inc.
New York, NY 10001
LAB-1556-1.0
Health Professional Information
{{section_name_patient}}
{{section_body_html_patient}}
Resources
Didn’t find what you were looking for? Contact us.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Report Adverse Event
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.